Fortis Therapeutics

Fortis Therapeutics is focused on immuno-oncology, specifically on developing an ADC for multiple myeloma and late-stage prostate cancer, including both the adenocarcinoma and neuroendocrine types.
BioSpace is proud to present its NextGen “Class of 2018,” a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.
Fortis Therapeutics, Inc., an immuno-oncology biotech developing FOR46, a novel antibody drug conjugate (ADC) against CD46, today announced the close of a $40 million Series A financing.
The Phase 1 trial of FOR46 in metastatic castration-resistant prostate cancer is planned to launch by the end of the year.
Thought-leading industry veteran brings two decades of life sciences and biotechnology experience to the company’s Board of Directors
  • NextGen Class of 2018